Eltoprazine dihydrochloride is primarily investigated for its potential therapeutic applications in treating various neurological and psychiatric conditions. It is being studied for its efficacy in managing aggression and impulsivity, particularly in disorders such as Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), and certain personality disorders. Its mechanism of action, which involves modulation of serotonin receptors, makes it a promising candidate for reducing aggressive behaviors without significant sedative effects.

Additionally, eltoprazine dihydrochloride is explored for its potential role in addressing motor disorders, including Parkinson’s disease and levodopa-induced dyskinesias. Its ability to influence dopaminergic pathways while balancing serotonin activity may help alleviate motor symptoms and improve patient quality of life. Preclinical and clinical trials continue to assess its safety, tolerability, and effectiveness in these applications, potentially offering a novel treatment option for complex neuropsychiatric and neurodegenerative conditions.